Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"

被引：0
|
作者：
Radtke, Jan Philipp [1 ,2 ]
Albers, Peter [3 ]
Giesel, Frederik Lars [4 ]
机构：
[1] Heinrich Heine Univ Dusseldorf, Univ Klinikum Dusseldorf, Klin Urol, Dusseldorf, Germany
[2] Deutsch Krebsforschungszentrum, Abt Radiol, Heidelberg, Germany
[3] Univ Klinikum Dusseldorf, Klin Urol, Dusseldorf, Germany
[4] Univ Dusseldorf, Klin Nukl Med, Nukl Med, Dusseldorf, Germany
来源：
AKTUELLE UROLOGIE | 2022年 / 53卷 / 02期
关键词：
THERAPY;
D O I：
10.1055/a-1707-6928
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Lu-PSMA-617 for metastatic castration-resistant Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2022, 53 (02) : 106 - 106
  • [32] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [33] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-617 versus cabazitaxel Comment
    Todenhoefer, Tilman
    AKTUELLE UROLOGIE, 2023, 54 (04)
  • [34] PET/CT with 68Ga-PSMA for monitoring the treatment of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
    Heinzel, A.
    Boghos, D.
    Mottaghy, F. M.
    Gaertner, F.
    Essler, M.
    von Mallek, D.
    Ahmadzadehfar, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S23 - S23
  • [35] Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer
    Tann, Mark
    Sims, Justin
    Auxier, Ashleigh
    Althouse, Sandra K.
    Salous, Tareq
    King, Jennifer
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 135 - 135
  • [36] 177Lu-PSMA-617 Radioligand Treatment in Elderly Patients with Metastatic Castration-resistant Prostate Cancer: Therapeutic Efficacy and Safety Assessment
    Sahin, Ertan
    Elboga, Umut
    Cimen, Ufuk
    Okuyan, Merve
    Cayirli, Yusuf Burak
    CURRENT RADIOPHARMACEUTICALS, 2024, 17 (04) : 356 - 363
  • [37] Excellent Response to Full-Dose 177Lu-PSMA-617 RLT in Metastatic Castration-Resistant Prostate Cancer With Transplant Kidney
    Mahdi, Raza Abbas
    Aggarwal, Piyush
    Kumar, Suraj
    Sood, Ashwani
    Paul, Davinder
    Mittal, Bhagwant Rai
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (10) : E470 - E471
  • [38] Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
    Rahbar, Kambiz
    Schmidt, Matthias
    Heinzel, Alexander
    Eppard, Elisabeth
    Bode, Axel
    Yordanova, Anna
    Claesener, Michael
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (09) : 1334 - 1338
  • [39] Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer-a state of the art review
    Heidegger, Isabel
    Kesch, Claudia
    Kretschmer, Alexander
    Tsaur, Igor
    Ceci, Francesco
    Valerio, Massimo
    Tilki, Derya
    Marra, Giancarlo
    Preisser, Felix
    Fankhauser, Christian D.
    Zattoni, Fabio
    Chiu, Peter
    Puche-Sanz, Ignacio
    Olivier, Jonathan
    van den Bergh, Roderik C. N.
    Kasivisvanathan, Veeru
    Pircher, Andreas
    Virgolini, Irene
    Gandaglia, Giorgio
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [40] PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Sandhu, Shahneen
    Joshua, Anthony M.
    Emmett, Louise
    Spain, Lavinia Anne
    Horvath, Lisa
    Crumbaker, Megan
    Anton, Angelyn
    Wallace, Roslyn
    Pasam, Anupama
    Bressel, Mathias
    Cassidy, Erin
    Banks, Patricia
    Dhiantravan, Nattakorn
    Akhurst, Timothy J.
    Kumar, Aravind Ravi
    Alipour, Ramin
    Scalzo, Mark
    Williams, Scott
    Hicks, Rodney
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345